Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

899 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study.
Morimoto K, Yamada T, Takeda T, Shiotsu S, Date K, Tamiya N, Goto Y, Kanda H, Chihara Y, Kunimatsu Y, Katayama Y, Iwasaku M, Tokuda S, Takayama K. Morimoto K, et al. Among authors: kanda h. Target Oncol. 2023 Sep;18(5):657-665. doi: 10.1007/s11523-023-00991-5. Epub 2023 Aug 23. Target Oncol. 2023. PMID: 37610516
Early Tumor Shrinkage as a Predictor of Favorable Treatment Outcomes in Patients With Extensive-Stage SCLC Who Received Programmed Cell Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy: A Prospective Observational Study.
Ishida M, Morimoto K, Yamada T, Takeda T, Shiotsu S, Date K, Harada T, Tamiya N, Chihara Y, Takemura Y, Yamada T, Kanda H, Iwasaku M, Tokuda S, Kim YH, Takayama K. Ishida M, et al. Among authors: kanda h. JTO Clin Res Rep. 2023 Feb 28;4(4):100493. doi: 10.1016/j.jtocrr.2023.100493. eCollection 2023 Apr. JTO Clin Res Rep. 2023. PMID: 37025120 Free PMC article.
Prospective Observational Study Evaluating the Prognostic Value of the G8 Screening Tool for Extensive-Stage Small Cell Lung Cancer Patients Who Received Programmed Death-Ligand 1 Inhibitor plus Platinum-Etoposide Chemotherapy.
Morimoto K, Yamada T, Takeda T, Shiotsu S, Date K, Harada T, Tamiya N, Chihara Y, Takemura Y, Yamada T, Kanda H, Ishida M, Yoshimura A, Iwasaku M, Tokuda S, Kim YH, Takayama K. Morimoto K, et al. Among authors: kanda h. Drugs Aging. 2023 Jun;40(6):563-571. doi: 10.1007/s40266-023-01034-4. Epub 2023 May 5. Drugs Aging. 2023. PMID: 37145245
Dopant-additive synergism enhances perovskite solar modules.
Ding B, Ding Y, Peng J, Romano-deGea J, Frederiksen LEK, Kanda H, Syzgantseva OA, Syzgantseva MA, Audinot JN, Bour J, Zhang S, Wirtz T, Fei Z, Dörflinger P, Shibayama N, Niu Y, Hu S, Zhang S, Tirani FF, Liu Y, Yang GJ, Brooks K, Hu L, Kinge S, Dyakonov V, Zhang X, Dai S, Dyson PJ, Nazeeruddin MK. Ding B, et al. Among authors: kanda h. Nature. 2024 Apr;628(8007):299-305. doi: 10.1038/s41586-024-07228-z. Epub 2024 Mar 4. Nature. 2024. PMID: 38438066 Free PMC article.
899 results